<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Multiple sclerosis: Pregnancy and postpartum care
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Multiple sclerosis: Pregnancy and postpartum care
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Multiple sclerosis: Pregnancy and postpartum care
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Men-Jean Lee, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Cathlyn Sullivan, DO
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer Graves, MD, PhD, MAS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Francisco González-Scarano, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 19, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1751618824">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system that is a leading cause of neurologic disability. MS proportionally affects women more than men by a ratio of approximately 2:1 to 3:1, and the mean age of onset of MS is approximately 30 years. Thus, the symptoms of MS commonly present in women of reproductive age, who need special considerations for pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/96016.html" rel="external">
          "Pathogenesis and epidemiology of multiple sclerosis"
         </a>
         .)
        </p>
        <p>
         This topic will review the care of patients with MS during pregnancy and the postpartum period. Pregnancy planning is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/135221.html" rel="external">
          "Multiple sclerosis: Pregnancy planning"
         </a>
         .)
        </p>
        <p>
         Other aspects of MS are discussed elsewhere:
        </p>
        <p>
         <a class="medical medical_review" href="/z/d/html/1691.html" rel="external">
          Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/96029.html" rel="external">
          Clinical presentation, course, and prognosis of multiple sclerosis in adults
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">
          Evaluation and diagnosis of multiple sclerosis in adults
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/1689.html" rel="external">
          Manifestations of multiple sclerosis in adults
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">
          Symptom management of multiple sclerosis in adults
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/1698.html" rel="external">
          Treatment of acute exacerbations of multiple sclerosis in adults
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">
          Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/129095.html" rel="external">
          Indications for switching or stopping disease-modifying therapy for multiple sclerosis
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/1686.html" rel="external">
          Treatment of secondary progressive multiple sclerosis in adults
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/128298.html" rel="external">
          Treatment of primary progressive multiple sclerosis in adults
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/129091.html" rel="external">
          Overview of disease-modifying therapies for multiple sclerosis
         </a>
        </p>
        <p class="headingAnchor" id="H2074774362">
         <span class="h1">
          MANAGEMENT IN PREGNANCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are multiple aspects of management to be considered during pregnancy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of preventive disease-modifying therapies (DMTs)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitoring
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of breakthrough acute attacks/relapses
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic MS symptom management
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mental and physical wellness measures
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4101273950">
         <span class="h2">
          Effect of pregnancy on MS disease course
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnancy does not have a deleterious impact on MS course. Rather, pregnancy is associated with a decrease in MS relapse rate, with the third trimester of pregnancy having the same potency of effect as most high-efficacy MS immune therapies. These issues are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/135221.html" rel="external">
          "Multiple sclerosis: Pregnancy planning"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1871411414">
         <span class="h2">
          Use of DMTs
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above, the MS relapse rate is generally decreased with pregnancy. For many women with mild to moderate disease, DMTs can be discontinued altogether with careful preconception planning. DMTs that are known or potential teratogens should be discontinued before pregnancy, if possible. However, DMT discontinuation may lead to an increased intrapartum and postpartum relapse rate, particularly for
         <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">
          natalizumab
         </a>
         and
         <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">
          fingolimod
         </a>
         . Decisions should be guided by age, severity and frequency of previous relapses, magnetic resonance imaging (MRI) activity, disease progression, disability, and risk of treatment discontinuation. Relapse prevention should be the primary goal, with careful planning for what treatments might be required if relapse does occur. (See
         <a class="medical medical_review" href="/z/d/html/135221.html" rel="external">
          "Multiple sclerosis: Pregnancy planning", section on 'Preconception planning and care'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1538156517">
         <span class="h2">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should be monitored during pregnancy by clinical follow-up, with careful attention to possible manifestations of MS disease activity including acute attacks (relapses), development of new MS lesions (particularly more than one) on brain or spine MRI, and possibly the onset or progression of sustained disability.
        </p>
        <p class="headingAnchor" id="H2690938432">
         <span class="h2">
          MRI in pregnancy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use without contrast
         </strong>
         – If MS reactivation is suspected during pregnancy and the findings could affect treatment course, then 1.5 Tesla low-field strength MRI without gadolinium contrast should be performed. Consensus recommendations published in 2021 from the Magnetic Resonance Imaging in Multiple Sclerosis, Consortium of Multiple Sclerosis Centres, and North American Imaging in Multiple Sclerosis Cooperative (MAGNIMS-CMSC-NAIMS) state that the use of MRI is not contraindicated during pregnancy, but its use should be decided on a case-by-case basis for clinical presentations that suggest MS disease activity or comorbid conditions [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Concerns with gadolinium
         </strong>
         – The 2021 MAGNIMS-CMSC-NAIMS guidelines consider gadolinium to be strictly contraindicated in pregnancy, despite the absence of convincing evidence of clinical harm [
         <a href="#rid1">
          1
         </a>
         ]. While inadvertent use during pregnancy has not been associated with adverse effects, gadolinium exposure in any trimester may have risks to the fetus that can continue into early childhood [
         <a href="#rid2">
          2
         </a>
         ]. In the absence of gadolinium contrast, new or enlarged T2 lesions on MRI are used as the radiologic marker of increased MS disease activity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The 2017 guidelines from the American College of Obstetricians and Gynecologists state that the use of gadolinium contrast should be limited in pregnancy but may be considered only if it significantly improves diagnostic performance and is expected to improve fetal or maternal outcome [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">
          "Diagnostic imaging in pregnant and lactating patients", section on 'Use of gadolinium'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H602307890">
         <span class="h2">
          Lumbar puncture
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although seldom necessary, lumbar puncture can be performed safely in pregnancy if needed to exclude an infectious or inflammatory condition other than MS (eg, to look for JC virus in a patient who had been receiving a high-efficacy DMT such as
         <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">
          natalizumab
         </a>
         ) or if needed for evaluation of an undiagnosed patient with symptoms suggestive of MS during pregnancy. Diagnostic testing to distinguish MS from other autoimmune encephalopathies should not be delayed due to pregnancy, especially if management may be affected.
        </p>
        <p class="headingAnchor" id="H3873090196">
         <span class="h2">
          Treatment of acute relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         During pregnancy, it is reasonable to treat MS relapse (also known as MS exacerbation or MS attack) if associated with functionally disabling symptoms in the second or third trimester [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         The mainstay of MS relapse treatment is intravenous (IV)
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         . As with all medications used in pregnancy, glucocorticoid use should be guided by patient education and shared decision-making. Treatment of relapse with glucocorticoids during pregnancy needs to account for the trimester of pregnancy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoids in the second and third trimester
         </strong>
         – Short-term, high-dose IV glucocorticoids are first-line treatment for MS relapse, typically given as 1 gram of IV
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         daily for three to five days. Methylprednisolone,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         are inactivated by placental 11-beta-hydroxysteroid dehydrogenase and do not enter the fetal circulation. Therefore, they are preferred in pregnancy [
         <a href="#rid4">
          4,5
         </a>
         ]. By contrast,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         and
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         are
         <strong>
          not
         </strong>
         preferred, given minimal metabolism at the placental interface resulting in increased amounts directed to the fetus. Ideally, oral glucocorticoids should be avoided in pregnancy due to high bioavailability to the fetus. However, this is not always feasible, since outpatient access to IV methylprednisolone may be limited in some settings. In such cases, the patient can be treated with the lowest therapeutic dose of oral methylprednisolone sufficient to manage the relapse symptoms, along with appropriate counseling on the risks of oral glucocorticoids. These risks include preeclampsia, pregnancy-induced hypertension, weight gain, hyperglycemia, gestational diabetes, gastrointestinal ulcers, and premature rupture of membranes. (See
         <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">
          "Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Glucocorticoids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoids in the first trimester
         </strong>
         – Glucocorticoid use in the first trimester is controversial, given evidence in older studies of an increased risk of craniofacial abnormalities (such as cleft lip and palate) and low birth weight [
         <a href="#rid5">
          5-8
         </a>
         ]. However, subsequent large studies have found no association of congenital abnormalities or low birth weight with early use of glucocorticoids [
         <a href="#rid9">
          9-11
         </a>
         ]. Given the controversy, some experts avoid glucocorticoid use in the first trimester, while other experts will treat relapse in the first trimester with IV
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         or
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         in a shared decision-making process with patients who are counseled about the possible small risk of craniofacial abnormalities and intrauterine growth restriction [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Plasma exchange
         </strong>
         – There are few data for treating refractory MS relapses in pregnancy. There is anecdotal evidence supporting therapeutic plasma exchange (PLEX) as a possible choice for relapses refractory to glucocorticoid treatment [
         <a href="#rid12">
          12-14
         </a>
         ]. Limited clinical trial and observational data in nonpregnant patients also suggest that PLEX is beneficial for MS relapse. The treatment of refractory MS relapse with PLEX in the general population is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1698.html" rel="external">
          "Treatment of acute exacerbations of multiple sclerosis in adults", section on 'Treatment of refractory relapse'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Note that patients with MS who are treated with
         <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">
          natalizumab
         </a>
         are at risk for developing an immune reconstitution inflammatory syndrome (IRIS) after withdrawal of natalizumab and restoration of immune response. This may occur in patients who develop progressive multifocal leukoencephalopathy (PML) as a complication of natalizumab treatment, but discontinuation of natalizumab can be associated with a severe rebound of MS disease activity, sometimes leading to a severe reaction similar to IRIS in the absence of PML [
         <a href="#rid15">
          15
         </a>
         ]. There is some concern that PLEX may accelerate IRIS in this setting [
         <a href="#rid16">
          16,17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1694.html" rel="external">
          "Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis", section on 'Inflammatory PML (PML-IRIS)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129091.html" rel="external">
          "Overview of disease-modifying therapies for multiple sclerosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2557193772">
         <span class="h2">
          Symptom management
         </span>
         <span class="headingEndMark">
          —
         </span>
         As relapses naturally decrease in pregnancy, often more challenging is the management of chronic MS symptoms in pregnancy. Bladder and fatigue symptoms may worsen with pregnancy, and some symptoms from medications may have certain contraindications in different trimesters of pregnancy. Management of depression and pain may also be challenging. (See
         <a class="medical medical_review" href="/z/d/html/1689.html" rel="external">
          "Manifestations of multiple sclerosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">
          "Symptom management of multiple sclerosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2490348452">
         <span class="h1">
          DELIVERY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The route of delivery for pregnant patients with MS is similar to delivery for pregnant patients in the general population, unless significant disability is present. Duration of hospital stay, rates of assisted vaginal delivery, and cesarean deliveries were not significantly different in women with MS than in women without MS [
         <a href="#rid18">
          18,19
         </a>
         ]. Other studies indicate that assisted vaginal delivery and cesarean section rates are higher in patients with more severe disability, but these are subject to bias of the obstetrician's perception [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         The choice of anesthesia should be based upon obstetric concerns [
         <a href="#rid20">
          20,21
         </a>
         ]. Epidural and single-shot spinal anesthesia techniques can be utilized in patients with MS. There is no evidence of harm with epidural anesthesia in patients with MS. Rates of epidural anesthesia are lower in patients with MS, but several studies show regional anesthesia use does not correlate with rate of postpartum relapse or disability progression [
         <a href="#rid22">
          22-24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/107587.html" rel="external">
          "Obstetric and nonobstetric anesthesia for patients with neurologic disorders", section on 'Multiple sclerosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3816975408">
         <span class="h1">
          POSTPARTUM CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postpartum patients are encouraged to have family and caregiver support to decrease stress and sleep deprivation, particularly those with active neurologic symptoms. They should continue their postpartum care with a maternal-fetal medicine specialist and neurologist to be attuned to potential MS flare, worsening depression, or worsening of other chronic MS symptoms.
        </p>
        <p class="headingAnchor" id="H164134198">
         <span class="h2">
          Relapse risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         The protective effect of pregnancy against relapse is lost in the postpartum period, and 20 to 30 percent of women may experience a relapse in this period. This risk is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/135221.html" rel="external">
          "Multiple sclerosis: Pregnancy planning", section on 'MS activity in pregnancy and postpartum'
         </a>
         .)
        </p>
        <p>
         Exclusive breastfeeding (see
         <a class="local">
          'Breastfeeding and MS'
         </a>
         below) may reduce this risk, but it is important to make a careful postpartum management plan with women in the third trimester in anticipation of the increased relapse risk.
        </p>
        <p class="headingAnchor" id="H2622101626">
         <span class="h2">
          Clinical evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         As already mentioned, the rate of MS relapses may increase in the first one to six months postpartum. Symptoms and need for neuroimaging should be addressed in a visit four to six weeks postdelivery [
         <a href="#rid4">
          4
         </a>
         ]. If a patient has not already been counseled about the increased risk of relapse (and potential signs and symptoms) during the postpartum period or is uncertain, it is reasonable to follow up within one week of delivery.
        </p>
        <p>
         The postpartum evaluation should cover the major manifestations of MS, including cognition, weakness, fatigue, gait and balance, bladder and bowel symptoms, pain, and social supports [
         <a href="#rid4">
          4
         </a>
         ]. Patients with MS have an increased risk of mood disorders and should be screened for the presence of postpartum depression. (See
         <a class="medical medical_review" href="/z/d/html/1704.html" rel="external">
          "Postpartum unipolar major depression: Epidemiology, clinical features, assessment, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1339966767">
         <span class="h2">
          MRI postpartum
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surveillance MRI to establish a new baseline is recommended within the first two to three months postpartum, particularly for women who have not yet resumed disease-modifying therapy (DMT), to look for evidence of silent MS disease activity [
         <a href="#rid1">
          1,4
         </a>
         ]. While there is no restriction for the use of MRI postpartum, consensus recommendations state that gadolinium should be used during lactation only if essential for patient management, despite lack of evidence associating gadolinium exposure with neonatal harm [
         <a href="#rid1">
          1
         </a>
         ]. Gadolinium administration does not require a washout period during lactation, as less than 1 percent is excreted in breast milk and less than 1 percent is absorbed from the neonatal gut [
         <a href="#rid25">
          25
         </a>
         ]. Therefore, breastfeeding should not be interrupted with gadolinium administration [
         <a href="#rid3">
          3
         </a>
         ]. If the patient prefers to completely avoid exposing the infant to gadolinium, the patient should "pump and dump" (ie, discard) breast milk for 24 hours following gadolinium infusion.
        </p>
        <p>
         Some experts obtain an MRI also when the infant starts taking some solid food, as they are not as reliant on calories from breast milk and may tolerate 24 hours of formula better than the solely breastfed infant.
        </p>
        <p class="headingAnchor" id="H2477095428">
         <span class="h2">
          Postpartum relapse treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids are first-line treatment for postpartum relapses.
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          Methylprednisolone
         </a>
         (typically 1 gram by intravenous [IV] infusion daily for three to five days) is preferred since it has very low transfer to breastmilk [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
         Limited retrospective data suggest that pulsed IV glucocorticoid treatment reduces the postpartum relapse rate, but high-quality data are lacking [
         <a href="#rid28">
          28,29
         </a>
         ]. Studies have shown no consistent benefit of intravenous immunoglobulin (
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         ) for relapse prevention in the postpartum period [
         <a href="#rid30">
          30-32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2651084033">
         <span class="h1">
          BREASTFEEDING AND MS
         </span>
        </p>
        <p class="headingAnchor" id="H3800085637">
         <span class="h2">
          Most women with MS can successfully breastfeed
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since breastfeeding is known to provide beneficial health effects for the newborn and mother, women with MS should be encouraged and supported to breastfeed. Exclusive breastfeeding has been associated with a reduction in postpartum MS relapse rates (see
         <a class="local">
          'Breastfeeding and MS relapse rate'
         </a>
         below). Medications must be accounted for, such as glucocorticoid use and disease-modifying therapies (DMTs).
        </p>
        <p class="headingAnchor" id="H2113002131">
         <span class="h2">
          Breastfeeding and DMTs
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who choose to breastfeed, one option is to defer DMT while maintaining breastfeeding, followed by a rapid breastfeeding wean and resumption of a high-efficacy DMT [
         <a href="#rid4">
          4
         </a>
         ]. Alternatively, it is reasonable to continue breastfeeding while using a DMT compatible with lactation (eg,
         <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">
          glatiramer acetate
         </a>
         , interferon [IFN]-beta formulation, or monoclonal antibody such as
         <a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">
          ocrelizumab
         </a>
         or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ), with counseling to the patient about what is known and not known about DMT use in breastfeeding.
        </p>
        <p>
         Many women choose to forgo DMTs while breastfeeding, as the effect of most DMTs on neonatal development is uncertain. Resumption of DMTs postpartum has to be measured against DMT excretion in breast milk and effect on the neonate (
         <a class="graphic graphic_table graphicRef138591" href="/z/d/graphic/138591.html" rel="external">
          table 1
         </a>
         ), so this requires a shared decision-making model of care [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="local">
          'Restarting DMT'
         </a>
         below.)
        </p>
        <p>
         The use of IFN-beta or
         <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">
          glatiramer acetate
         </a>
         is probably safe during breastfeeding [
         <a href="#rid34">
          34
         </a>
         ]. IFN-beta is secreted at minimal levels in breast milk, as the levels are below the level of detection, and no side effects have been observed in breastfed infants [
         <a href="#rid35">
          35
         </a>
         ]. It is unknown if glatiramer acetate is secreted in breast milk, but no adverse effects have been reported in breastfed infants [
         <a href="#rid34">
          34
         </a>
         ]. Although data are limited, the B-cell depleting monoclonal antibody DMTs are probably compatible with breastfeeding (
         <a class="graphic graphic_table graphicRef138591" href="/z/d/graphic/138591.html" rel="external">
          table 1
         </a>
         ), while DMTs best avoided during breastfeeding (
         <a class="graphic graphic_table graphicRef138591" href="/z/d/graphic/138591.html" rel="external">
          table 1
         </a>
         ) include the fumarates (eg,
         <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">
          dimethyl fumarate
         </a>
         ),
         <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">
          mitoxantrone
         </a>
         , sphingosine 1-phosphate receptor modulators (
         <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">
          fingolimod
         </a>
         ,
         <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">
          siponimod
         </a>
         ,
         <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">
          ozanimod
         </a>
         , and
         <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">
          ponesimod
         </a>
         ),
         <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">
          teriflunomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         , and
         <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">
          cladribine
         </a>
         [
         <a href="#rid4">
          4,36
         </a>
         ]. Alemtuzumab has been detected in the offspring of lactating mice, but data for human breast milk are lacking [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H279298759">
         <span class="h2">
          Breastfeeding and glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids are minimally excreted in breast milk. Patients on doses as high as 80 mg daily were seen to have less than a 10 percent increase in the neonate's overall endogenous steroid levels. If patient preference is to completely avoid glucocorticoid effect on the neonate, this can be accomplished by "pumping and dumping" for 24 to 48 hours after glucocorticoid infusion [
         <a href="#rid26">
          26,39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2071921134">
         <span class="h2">
          Breastfeeding and MS relapse rate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several reports have found that exclusive breastfeeding is associated with a reduction in postpartum MS relapse rates [
         <a href="#rid40">
          40-42
         </a>
         ]. In two prospective cohort studies, exclusive breastfeeding for at least two months postpartum was associated with a reduced rate of MS relapses [
         <a href="#rid40">
          40,41
         </a>
         ]; the biologic mechanism of this association is not yet clear, but the authors speculated that lactational suppression of menses during exclusive breastfeeding led to a reduced risk of postpartum relapses. Similarly, a 2020 systematic review and meta-analysis of observational data found that breastfeeding was associated with a reduced risk of postpartum MS relapse (pooled odds ratio [OR] 0.63, 95% CI 0.45-0.88) [
         <a href="#rid43">
          43
         </a>
         ]. A subsequent observational study of 1998 pregnancies from 1619 women with MS also found that breastfeeding was associated with a reduced risk of relapse (hazard ratio [HR] 0.61, 95% CI 0.41-0.91); the study adjusted for potential confounders including prior disease activity and resumption of DMT [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         Earlier data suggested that postpartum relapse rates primarily reflected the severity of prepartum MS disease activity and that the rate of breastfeeding was inversely proportional to the underlying disease severity; that is, women with milder forms of MS were more likely to breastfeed and forego DMTs, which are generally avoided during lactation, whereas women with more active MS avoided lactation because of the need to resume DMTs [
         <a href="#rid22">
          22,45-48
         </a>
         ]. However, this likely led to confounding by indication, since women with more active MS on DMT were usually not included [
         <a href="#rid48">
          48,49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H309370545">
         <span class="h1">
          RESTARTING DMT
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients not breastfeeding
         </strong>
         – If the patient does not wish to breastfeed, then disease-modifying therapy (DMT) treatment should be restarted within three weeks of delivery. This is especially impactful on patients with high preconception disease activity. Interferon (IFN)-beta and
         <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">
          glatiramer acetate
         </a>
         decrease reactivation of disease by 50 percent when given within three months and decrease risk of relapse for at least one year [
         <a href="#rid50">
          50,51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients who are breastfeeding
         </strong>
         – The use of DMTs with breastfeeding is reviewed above. (See
         <a class="local">
          'Breastfeeding and DMTs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4224380388">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management during pregnancy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Use of DMTs
         </strong>
         – Pregnancy is associated with a decrease in multiple sclerosis (MS) relapse rate. The approach to use of disease-modifying therapies (DMTs) in pregnancy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/135221.html" rel="external">
          "Multiple sclerosis: Pregnancy planning", section on 'Use of disease-modifying therapies (DMTs)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Monitoring
         </strong>
         – Patients should be monitored for MS disease activity including acute attacks (relapses) and development of new MS lesions. MRI should be used sparingly for clinical presentations that suggest MS disease activity or comorbid conditions. Gadolinium contrast is contraindicated during pregnancy. (See
         <a class="local">
          'Monitoring'
         </a>
         above and
         <a class="local">
          'MRI in pregnancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment of acute relapse
         </strong>
         – Acute MS attacks (relapses) causing disabling symptoms during the second and third trimesters of pregnancy are treated with intravenous glucocorticoids. (See
         <a class="local">
          'Management in pregnancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Delivery
         </strong>
         – The route of delivery for pregnant patients with MS is similar to delivery for pregnant patients in the general population. The choice of anesthesia should be based upon obstetric concerns. (See
         <a class="local">
          'Delivery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postpartum care
         </strong>
         – The rate of MS relapses may increase in the first one to six months postpartum. Patients with MS should have a comprehensive postpartum evaluation, including imaging to establish a new MRI baseline. Gadolinium contrast should be used during lactation only if essential for patient management; to avoid exposing the infant to gadolinium, the patient should "pump and dump" (ie, discard) breast milk for 24 hours following gadolinium infusion. Only a tiny fraction of gadolinium is excreted into breast milk; thus, with consent, a patient can receive gadolinium and continue to breastfeed if no other food source is available. Glucocorticoids are first-line treatment for postpartum relapses. (See
         <a class="medical medical_review" href="/z/d/html/135221.html" rel="external">
          "Multiple sclerosis: Pregnancy planning", section on 'MS activity in pregnancy and postpartum'
         </a>
         and
         <a class="local">
          'Clinical evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Breastfeeding
         </strong>
         – Since breastfeeding is known to provide beneficial health effects for the newborn and mother, women with MS should be encouraged and supported to breastfeed. Exclusive breastfeeding has been associated with a reduction in postpartum MS relapse rates. Many women thus choose to forgo DMTs while breastfeeding if MS symptoms can be managed without them. However, breastfeeding is not as protective as pregnancy, and for women with more aggressive disease, DMTs that are likely safe for breastfeeding include the interferon (IFN)-beta,
         <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">
          glatiramer acetate
         </a>
         , and possibly the B-cell depleting monoclonal antibodies (
         <a class="graphic graphic_table graphicRef138591" href="/z/d/graphic/138591.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Breastfeeding and MS'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Restarting DMT
         </strong>
         – For patients who do not breastfeed, DMT should be restarted within three weeks of delivery (per consensus opinion), balancing any risks of infection or clotting for the mother. (See
         <a class="local">
          'Restarting DMT'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021; 20:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Webb JA, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol 2005; 15:1234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee Opinion No. 723: Guidelines for Diagnostic Imaging During Pregnancy and Lactation. Obstet Gynecol 2017; 130:e210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bove RM, Houtchens MK. Pregnancy Management in Multiple Sclerosis and Other Demyelinating Diseases. Continuum (Minneap Minn) 2022; 28:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACOG Committee Opinion No. 776 Summary: Immune Modulating Therapies in Pregnancy and Lactation. Obstet Gynecol 2019; 133:846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carmichael SL, Shaw GM, Ma C, et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007; 197:585.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66:1560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bay Bjørn AM, Ehrenstein V, Hundborg HH, et al. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Ther 2014; 21:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bandoli G, Palmsten K, Forbess Smith CJ, Chambers CD. A Review of Systemic Corticosteroid Use in Pregnancy and the Risk of Select Pregnancy and Birth Outcomes. Rheum Dis Clin North Am 2017; 43:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skuladottir H, Wilcox AJ, Ma C, et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A Clin Mol Teratol 2014; 100:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox JL, Koepsell SA, Shunkwiler SM. Therapeutic plasma exchange and pregnancy: A case report and guidelines for performing plasma exchange in a pregnant patient. J Clin Apher 2017; 32:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalka L, Harb A, Mikesell K, Gordon Perue G. Medically Refractory Multiple Sclerosis Is Successfully Treated with Plasmapheresis in a Super Morbidly Obese Pregnant Patient. Case Rep Neurol Med 2020; 2020:4536145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wind M, Gaasbeek AGA, Oosten LEM, et al. Therapeutic plasma exchange in pregnancy: A literature review. Eur J Obstet Gynecol Reprod Biol 2021; 260:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011; 68:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011; 77:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, et al. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases. Clin Ther 2016; 38:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canibaño B, Deleu D, Mesraoua B, et al. Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations. J Drug Assess 2020; 9:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Kop ML, Pearce MS, Dahlgren L, et al. Neonatal and delivery outcomes in women with multiple sclerosis. Ann Neurol 2011; 70:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bove R, Alwan S, Friedman JM, et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol 2014; 124:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrero S, Pretta S, Ragni N. Multiple sclerosis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 115:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu E, Zhao Y, Dahlgren L, et al. Obstetrical epidural and spinal anesthesia in multiple sclerosis. J Neurol 2013; 260:2620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pastò L, Portaccio E, Ghezzi A, et al. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurol 2012; 12:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundgren PC, Leander P. Is administration of gadolinium-based contrast media to pregnant women and small children justified? J Magn Reson Imaging 2011; 34:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boz C, Terzi M, Zengin Karahan S, et al. Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis. Mult Scler 2018; 24:1205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper SD, Felkins K, Baker TE, Hale TW. Transfer of methylprednisolone into breast milk in a mother with multiple sclerosis. J Hum Lact 2015; 31:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avila-Ornelas J, Avila M, Stosic M, et al. The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosis. Int J MS Care 2011; 13:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Seze J, Chapelotte M, Delalande S, et al. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 2004; 10:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler 2007; 13:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fragoso YD, Adoni T, Alves-Leon SV, et al. Postpartum Treatment With Immunoglobulin Does Not Prevent Relapses of Multiple Sclerosis in the Mother. Health Care Women Int 2015; 36:1072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosa GR, O'Brien AT, Nogueira EAG, et al. There is no benefit in the use of postnatal intravenous immunoglobulin for the prevention of relapses of multiple sclerosis: findings from a systematic review and meta-analysis. Arq Neuropsiquiatr 2018; 76:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almas S, Vance J, Baker T, Hale T. Management of Multiple Sclerosis in the Breastfeeding Mother. Mult Scler Int 2016; 2016:6527458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langer-Gould AM. Pregnancy and Family Planning in Multiple Sclerosis. Continuum (Minneap Minn) 2019; 25:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hale TW, Siddiqui AA, Baker TE. Transfer of interferon β-1a into human breastmilk. Breastfeed Med 2012; 7:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coyle PK, Oh J, Magyari M, et al. Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review. Mult Scler Relat Disord 2019; 32:54.
          </a>
         </li>
         <li class="breakAll">
          Alemtuzumab. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Alemtuzumab. 2022 May 15. Available at: https://www.ncbi.nlm.nih.gov/books/NBK501803/ (Accessed on August 09, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capone F, Albanese A, Quadri G, et al. Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review. Front Neurol 2022; 13:851413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol 2013; 260:1202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langer-Gould A, Huang SM, Gupta R, et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 2009; 66:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hellwig K, Rockhoff M, Herbstritt S, et al. Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses. JAMA Neurol 2015; 72:1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langer-Gould A, Smith JB, Albers KB, et al. Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Neurology 2020; 94:e1939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krysko KM, Rutatangwa A, Graves J, et al. Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses: A Systematic Review and Meta-analysis. JAMA Neurol 2020; 77:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeh WZ, Widyastuti PA, Van der Walt A, et al. Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kieseier BC, Wiendl H. Postpartum disease activity and breastfeeding in multiple sclerosis revisited. Neurology 2010; 75:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Portaccio E, Ghezzi A, Hakiki B, et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology 2011; 77:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Airas L, Jalkanen A, Alanen A, et al. Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis. Neurology 2010; 75:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pakpoor J, Disanto G, Lacey MV, et al. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol 2012; 259:2246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vukusic S, Durand-Dubief F, Benoit A, et al. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. Mult Scler 2015; 21:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006; 12:309.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 138599 Version 1.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34139157" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15609057" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The use of iodinated and gadolinium contrast media during pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28937575" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Committee Opinion No. 723: Guidelines for Diagnostic Imaging During Pregnancy and Lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35133309" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Pregnancy Management in Multiple Sclerosis and Other Demyelinating Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30913195" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : ACOG Committee Opinion No. 776 Summary: Immune Modulating Therapies in Pregnancy and Lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18060943" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Maternal corticosteroid use and orofacial clefts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17660219" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11091360" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23011170" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28711148" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A Review of Systemic Corticosteroid Use in Pregnancy and the Risk of Select Pregnancy and Birth Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24777675" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Corticosteroid use and risk of orofacial clefts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27142429" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Therapeutic plasma exchange and pregnancy: A case report and guidelines for performing plasma exchange in a pregnant patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32313710" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Medically Refractory Multiple Sclerosis Is Successfully Treated with Plasmapheresis in a Super Morbidly Obese Pregnant Patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33713886" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Therapeutic plasma exchange in pregnancy: A literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20937940" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21832229" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26856928" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32128285" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21710652" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Neonatal and delivery outcomes in women with multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25415167" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15223156" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Multiple sclerosis: management issues during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15130950" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23864398" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Obstetrical epidural and spinal anesthesia in multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23276328" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21928308" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Is administration of gadolinium-based contrast media to pregnant women and small children justified?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28649909" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25691380" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Transfer of methylprednisolone into breast milk in a mother with multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24453710" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15471379" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17881400" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25187102" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Postpartum Treatment With Immunoglobulin Does Not Prevent Relapses of Multiple Sclerosis in the Mother.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29972417" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : There is no benefit in the use of postnatal intravenous immunoglobulin for the prevention of relapses of multiple sclerosis: findings from a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26966579" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Management of Multiple Sclerosis in the Breastfeeding Mother.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31162316" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Pregnancy and Family Planning in Multiple Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21988602" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Transfer of interferonβ-1a into human breastmilk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31030020" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31030020" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35493841" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22926165" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Multiple sclerosis and pregnancy: therapeutic considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19506118" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26322399" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32284359" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31816024" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33879599" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9682040" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20679632" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Postpartum disease activity and breastfeeding in multiple sclerosis revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21734184" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Breastfeeding is not related to postpartum relapses in multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20679640" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22619059" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Breastfeeding and multiple sclerosis relapses: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25305253" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16764344" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
